Cancer cells cheat death in a number of ways, dividing and multiplying infinitely in a patient’s body. But by tinkering with glioblastoma cells a preclinical proof-of-concept study, researchers from UC San Francisco report that they have found a way to disrupt one of those “immortality switches.”
It’s a first glimpse at the science behind Telo Therapeutics, a GlaxoSmithKline-partnered biotech upstart founded by UCSF neuro-oncology professor Joseph Costello and one of his former PhD students, Robert Bell. Costello is the senior author of the study while Bell is listed as a co-author.
Their breakthrough here begins with telomere, the cell lifespan-controlling chromosome cap that’s inspired considerable interest in both anti-aging (to prolong a functional cell’s life) and cancer (to hasten a tumor cell’s death).
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 37,700+ biopharma pros who read Endpoints News by email every day.Free Subscription